Aytu BioPharma up on new patent for lead therapy

Aytu Biopharma

14/09/2022 16:11

** Drug developer Aytu BioPharma Inc's  AYTU.O  shares rise
1.27% to 22 cents
    ** Co secures fourth patent for lead drug candidate AR101,
being developed as a potential treatment for vascular
Ehlers-Danlos Syndrome (VEDS)  urn:newsml:reuters.com:*:nFWN30L1MU 
    ** VEDS is a more severe form of the Ehlers-Danlos syndrome,
a group of inherited disorders that affects connective tissues
including in the skin, joints and blood vessel walls
    ** Patent, licensed from Johns Hopkins University, will
expire in Sept. 2041, assuming no patent term extension - AYTU
    ** 2 brokerages covering the stock rate "buy"; their median
PT is $5.50 - Refinitiv data
    ** Including session gains, stock down ~93% YTD 

 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com;))